AstraZeneca's Trixeo EU Approval & Boehringer's $250M Deal | Pharma and Biotech Daily

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the dynamic landscape of scientific advances and strategic collaborations shaping patient care and drug development globally. AstraZeneca recently achieved a significant milestone with the European Union's approval of Trixeo, a combination therapy for asthma. This approval follows a successful Phase 3 trial, highlighting its effectiveness i...